Cu-64 oxo-trastuzumab

Cu-64 oxo-trastuzumab (also known as [64Cu]-Oxo-DO3A-trastuzumab) is a research-stage radiolabeled immunoconjugate designed for positron emission tomography (PET) imaging of HER2-positive cancers. It consists of the humanized monoclonal antibody trastuzumab, which targets the human epidermal growth factor receptor 2 (HER2/neu), conjugated to the bifunctional chelator 1-oxa-4,7,10-triazacyclododecane-5-S-(4-isothiocyanatobenzyl)-4,7,10-triacetic acid (p-SCN-Bn-Oxo-DO3A) and radiolabeled with the positron-emitting radioisotope copper-64 (Cu-64). Developed by researchers at MDS Nordion, the BC Cancer Agency, and Macrocyclics, this agent is designed to offer superior radiolabeling efficiency and in vivo stability compared to traditional DOTA-conjugated alternatives, enabling clearer and earlier visualization of HER2-expressing tumors with lower liver accumulation of radioactivity.

Other names

[64Cu]-Oxo-DO3A-conjugated trastuzumab[64Cu]-Oxo-DO3A-trastuzumab[64Cu]-Oxo-trastuzumab64Cu-Labeled Oxo-DO3A-conjugated trastuzumab64Cu-Oxo-DO3A-trastuzumabcopper-64 oxo-trastuzumabcopper64 oxo-trastuzumabcopper 64 oxo-trastuzumab